Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
QLTI's Cash to Debt is ranked higher than
90% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. QLTI: No Debt )
QLTI' s 10-Year Cash to Debt Range
Min: 0.7   Max: No Debt
Current: No Debt

Interest Coverage No Debt
QLTI's Interest Coverage is ranked higher than
96% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. QLTI: No Debt )
QLTI' s 10-Year Interest Coverage Range
Min: 24.57   Max: 9999.99
Current: No Debt

24.57
9999.99
F-Score: 3
Z-Score: 24.81
M-Score: -3.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROE (%) -16.65
QLTI's ROE (%) is ranked higher than
79% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. QLTI: -16.65 )
QLTI' s 10-Year ROE (%) Range
Min: -53.39   Max: 51.72
Current: -16.65

-53.39
51.72
ROA (%) -16.02
QLTI's ROA (%) is ranked higher than
78% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. QLTI: -16.02 )
QLTI' s 10-Year ROA (%) Range
Min: -48.78   Max: 28.78
Current: -16.02

-48.78
28.78
ROC (Joel Greenblatt) (%) -138.74
QLTI's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. QLTI: -138.74 )
QLTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1043.82   Max: 55.57
Current: -138.74

-1043.82
55.57
EBITDA Growth (3Y)(%) 5.80
QLTI's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. QLTI: 5.80 )
QLTI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -34.3   Max: 85.3
Current: 5.8

-34.3
85.3
EPS Growth (3Y)(%) 44.10
QLTI's EPS Growth (3Y)(%) is ranked higher than
95% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. QLTI: 44.10 )
QLTI' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.5   Max: 103.9
Current: 44.1

-66.5
103.9
» QLTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

QLTI Guru Trades in Q4 2013

Jim Simons 115,164 sh (+22.95%)
» More
Q1 2014

QLTI Guru Trades in Q1 2014

Jim Simons 95,164 sh (-17.37%)
» More
Q2 2014

QLTI Guru Trades in Q2 2014

Jim Simons 52,364 sh (-44.97%)
» More
Q3 2014

QLTI Guru Trades in Q3 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with QLTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2011-09-30 Sold Out 0.004%$5.65 - $7.57 $ 3.7-46%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.42
QLTI's P/B is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. QLTI: 1.42 )
QLTI' s 10-Year P/B Range
Min: 0.27   Max: 4.52
Current: 1.42

0.27
4.52
EV-to-EBIT -2.21
QLTI's EV-to-EBIT is ranked higher than
54% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QLTI: -2.21 )
QLTI' s 10-Year EV-to-EBIT Range
Min: -16.9   Max: 27.4
Current: -2.21

-16.9
27.4
Shiller P/E 22.53
QLTI's Shiller P/E is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QLTI: 22.53 )
QLTI' s 10-Year Shiller P/E Range
Min: 33.73   Max: 524.5
Current: 22.53

33.73
524.5
Current Ratio 38.81
QLTI's Current Ratio is ranked higher than
99% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. QLTI: 38.81 )
QLTI' s 10-Year Current Ratio Range
Min: 1.1   Max: 85.25
Current: 38.81

1.1
85.25
Quick Ratio 38.81
QLTI's Quick Ratio is ranked higher than
99% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. QLTI: 38.81 )
QLTI' s 10-Year Quick Ratio Range
Min: 1.07   Max: 85.25
Current: 38.81

1.07
85.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.50
QLTI's Price/Net Cash is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. QLTI: 1.50 )
QLTI' s 10-Year Price/Net Cash Range
Min: 1.07   Max: 87
Current: 1.5

1.07
87
Price/Net Current Asset Value 1.46
QLTI's Price/Net Current Asset Value is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. QLTI: 1.46 )
QLTI' s 10-Year Price/Net Current Asset Value Range
Min: 0.86   Max: 443.75
Current: 1.46

0.86
443.75
Price/Tangible Book 1.42
QLTI's Price/Tangible Book is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. QLTI: 1.42 )
QLTI' s 10-Year Price/Tangible Book Range
Min: 0.37   Max: 24.31
Current: 1.42

0.37
24.31
Price/DCF (Projected) 1.78
QLTI's Price/DCF (Projected) is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QLTI: 1.78 )
QLTI' s 10-Year Price/DCF (Projected) Range
Min: 0.28   Max: 250
Current: 1.78

0.28
250
Earnings Yield (Greenblatt) -45.20
QLTI's Earnings Yield (Greenblatt) is ranked higher than
51% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. QLTI: -45.20 )
QLTI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 432.7
Current: -45.2

3.6
432.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QLT.Canada, QLT.Germany,
QLT Inc was formed in 1981 under the laws of the Province of British Columbia. It is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians. The Company is developing QLT091001, a synthetic retinoid compound for the potential treatment of certain age-related and inherited retinal degenerative diseases. Its competitors include pharmaceutical and biopharmaceutical companies. The research and development, preclinical studies and clinical trials, and ultimately, the manufacturing, marketing and labelling of its products, are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries.
» More Articles for QLTI

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX Aug 13 2012 
QLT Inc. Reports Operating Results (10-K) Mar 01 2011 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 3,000 Shares Nov 08 2010 
QLT Inc. Reports Operating Results (10-Q) Nov 03 2010 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 5,000 Shares Jun 23 2010 
QLT Inc. (QLTI) CFO Cameron Nelson buys 10,000 Shares Nov 10 2009 
QLT Inc. Reports Operating Results (10-Q) Nov 06 2009 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 10,000 Shares Nov 04 2009 
QLT Inc. Reports Operating Results (10-Q) Aug 06 2009 
QLT Announces Second Quarter Results for 2009 Jul 28 2009 

More From Other Websites
QLT INC/BC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events,... Dec 16 2014
QLT Announces Results of Annual General Meeting of Shareholders Dec 16 2014
QLT Announces Results of Annual General Meeting of Shareholders Dec 16 2014
QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in... Dec 05 2014
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 05 2014
QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in... Dec 05 2014
QLT Announces Departure of Chief Financial Officer Dec 02 2014
QLT INC/BC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Dec 02 2014
QLT Announces Departure of Chief Financial Officer Dec 02 2014
QLT (QLTI) Is in Oversold Territory: What's Next? Nov 10 2014
QLT INC/BC Financials Nov 04 2014
QLT (QLTI) Reports Narrower-than-Expected Q3 Loss Oct 30 2014
QLT Announces Third Quarter 2014 Results Oct 28 2014
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 28 2014
QLT Announces Third Quarter 2014 Results Oct 28 2014
QLT INC/BC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Oct 27 2014
QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer Oct 24 2014
QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer Oct 24 2014
Endo Buyout Of Auxilium Joins Two Changing Firms Oct 09 2014
QLT INC/BC Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events,... Oct 09 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK